Applied to a combinatorial library of over 2 million drugpairs, AI-DrugNet identified 233,269 potential AD drug combinationsand highlighted five key target genes (AGTR1, FEN1, NADSYN1, PDHB,PSMB2) associated with brain injury and AD progression. Here, NADSYN1 is linked to Alzheimer disease.